We believe our work will direct efforts in the treatment of PCa in particular, but also for other cancers, by stimulating a systematic re-evaluation of CHKA as a therapeutic target, especially in tumors where it is overexpressed and may exhibit chaperone-analogous effects on other oncogenic proteins. Here, CHKA is linked to cancer.